Viatris’s CEO Sees a Unique Drug Business. The Stock Fell 12.5% in Its First Year.

Investors person yet to lukewarm to Viatris, created a twelvemonth agone this week by the merger betwixt a Pfizer spinoff and the generic drugmaker Mylan, but its CEO says that the institution is doing good and offers investors an extraordinarily wide scope of products.

“The happening that’s chiseled from galore companies retired determination is the portfolio,” said Viatris (ticker: VTRS) CEO Michael Goettler, who antecedently ran the Pfizer (PFE) part known arsenic Upjohn. That business, which specialized successful selling off-patent drugs successful overseas markets, completed...